Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
Strategies to improve male partner involvement in microbicide research needed

Vaginal microbicides were partially developed in response to power differentials within sexual relationships and gender norms that make it difficult for women to negotiate other forms of HIV

Published
17 December 2014
By
Lesley Odendal
Looking to a New Era for Women's HIV Prevention: Zeda Rosenberg

Zeda Rosenberg, Chief Executive Offiver of the International Partnership for Microbicides, says: "While there is much progress to celebrate in HIV treatment and prevention, protecting women remains a major challenge. AIDS is the number-one killer of women ages 15 to 44 worldwide. Women are biologically more vulnerable to infection and face deep-rooted gender inequities that increase their risk. In sub-Saharan Africa, where the epidemic has taken the greatest toll, young women are at least twice as likely to contract HIV as young men."

Published
26 November 2014
From
Huffington Post
As strategies to prevent HIV and unintended pregnancies evolve, concepts of “multi-purpose technologies” raise a familiar question . . .

What do women want? While two trials test vaginal rings to fight HIV, market research highlights respondents’ interests in different options.

Published
14 November 2014
From
Science Speaks
Semen directly impairs effectiveness of microbicides that target HIV

Most microbicides work by targeting the virus itself, attempting to break it down or blocking its ability to infect a cell. However, the heightened infectiousness of HIV in the presence of semen appears to over-power any anti-viral effects the microbicides possess. The one exception to this finding is a different type of microbicide that acts on the host cells' receptors, stopping the virus from latching on from within. In the current study, this microbicide, [containing the drug called] called Maraviroc, was equally effective in preventing infection both with and without the presence of semen.

Published
13 November 2014
From
MedicalXpress
Current State of Rectally-applied PrEP

A recent journal article reviewed the challenges and successes in developing rectal microbicides, including the state of the current field, which we summarize here.

Published
11 November 2014
From
BETA blog
Misunderstanding of questions regarding anal sex in microbicide HIV prevention trial

There was widespread misunderstanding and misinterpretation of questions about anal sex being asked of participants in the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial,

Published
10 November 2014
By
Lesley Odendal
HIV R4P: With combined HIV biomedical prevention approaches come optimism, circumspection

At this first international meeting to bring researchers from all biomedical HIV prevention approaches together under one roof, neither the time and disappointments leading up to this point, or the uncertainty of how much more time lies ahead, did anything to dampen a sense of optimism and ambition that AVAC director Mitchell Warren sums up as “momentum.”

Published
05 November 2014
From
Science Speaks
Dissolving Tampons Deliver HIV Drugs (and Maybe Contraception, Too)

University of Washington researchers have created a discreet, quick-dissolving tampon out of silk-line fibers to protect women from HIV. The researchers would ideally like to develop a tampon to protect against HIV, herpes, and pregnancy — an all-in-one shield against the risks of sex. This could prove especially useful in developing countries, where women may not have easy access to other kinds of birth control.

Published
04 November 2014
From
Healthline News
Model Explains Why HIV Prevention Dosing Differs by Sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex. This finding helps explain why two large clinical trials testing HIV pre-exposure prophylaxis, or PrEP, in women failed to show efficacy

Published
31 October 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
Tenofovir gel use associated with lower HSV-2 risk in women

The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by 46% (aIRR:0.54, 95%CI:0.30-0.97, p = 0.038) among women who regularly used the vaginal gel containing

Published
30 October 2014
By
Lesley Odendal
← First12345...19Next →

Filter by country